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ABSTRACT 49 
 50 
The metabolic fate of dietary n-3 docosapentaenoic acid (DPA) in mammals is currently 51 
unknown. The aim of this study was to determine the extent of conversion of dietary 52 
DPA to docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in rats. Four 53 
groups of male weanling Sprague Dawley rats (aged 5 weeks) were given 50 mg of 54 
DPA, EPA, DHA or oleic acid, daily for 7 days by gavage. At the end of the treatment 55 
period the tissues were analysed for concentrations of long chain polyunsaturated fatty 56 
acids (PUFA). DPA supplementation led to significant increases in DPA concentration 57 
in all tissues, with largest increase being in adipose (5 fold) and smallest increase being 58 
in brain (1.1 fold). DPA supplementation significantly increased the concentration of 59 
DHA in liver and the concentration of EPA in liver, heart and skeletal muscle, 60 
presumably by the process of retroconversion. EPA supplementation significantly 61 
increased the concentration of EPA and DPA in liver, heart and skeletal muscle and the 62 
DHA concentration in liver. DHA supplementation elevated the DHA levels in all 63 
tissues and EPA levels in the liver. Adipose was the main tissue site for accumulation of 64 
DPA, EPA and DHA. This data suggests that dietary DPA can be converted to DHA in 65 
the liver, in a short term study, and that in addition it is partly retro-converted to EPA in 66 
liver, adipose, heart and skeletal muscle. Future studies should examine the 67 
physiological effect of DPA in tissues such as liver and heart. 68 
 69 
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 83 
INTRODUCTION 84 
 85 
The interest in n-3 polyunsaturated fatty acids (PUFA) developed rapidly after two 86 
Nobel Prize winning discoveries of particular prostaglandins, metabolites of arachidonic 87 
acid, by Vane and Samuelson in the late 60’s and early 70’s (1). Since then there have 88 
been many studies suggesting the beneficial effects of n-3 fatty acids in reducing risk of 89 
cardiovascular events, diabetes, inhibiting growth of tumour cells, modulating gene 90 
expression and anti inflammatory activity 
(2-7)
. The parent n-3 PUFA is alpha-linolenic 91 
acid (ALA; 18:3n-3), which is found in high concentration in some plant oils. In 92 
mammals, some of the ingested ALA is metabolised to long chain n-3 PUFA (LCPn-3) 93 
namely eicosapentaenoic acid (EPA; 20:5n-3), docosapentaenoic acid (DPA; 22:5n-3) 94 
and docosahexaenoic acid (DHA; 22:6n-3) by a series of desaturations and elongations 95 
(see Fig 1). This metabolic processing of ALA to DHA is inefficient 
(8)
 and much of the 96 
ingested ALA is either deposited in tissue adipose stores as ALA or catabolised by 97 
mitochondrial beta-oxidation to yield energy (ATP) and carbon dioxide 
(9)
. Many 98 
studies have reported that feeding relatively high levels of ALA in either animals or 99 
humans leads to increased DPA levels, but not DHA levels, suggesting the steps 100 
between DPA and DHA are rate limiting steps in this metabolic pathway 
(10, 11)
. In 101 
contrast, ingested DHA is rapidly and efficiently deposited in brain, liver and other 102 
tissues 
(12)
. There is not much literature available on fate of DPA. Two cell culture 103 
studies have looked at the effect of DPA supplementation in endothelial cells and 104 
hepatocytes, respectively, and reported that DPA supplementation increases both DPA 105 
and EPA levels but not DHA in these cells 
(13, 14)
. However, no animal studies have been 106 
conducted to investigate the conversion of pure DPA to DHA in mammals, presumably 107 
because DPA has only recently become available for in vivo studies (in milligram 108 
amounts). DPA is found in common foods like fish, fish oil, lean red meat and n-3-109 
enriched eggs 
(15)
 therefore it is important to understand the metabolic fate of DPA. In 110 
this paper we report the effect of DPA supplementation on DPA, EPA and DHA 111 
concentrations in rat tissues. The hypothesis being tested was that dietary 112 
supplementation of DPA will increase both tissue DHA and EPA levels.  The novelty of 113 
this study is that it focuses on the metabolism of DPA in a rodent model, which has not 114 
been investigated before.  115 
 116 
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MATERIALS AND METHODS  117 
 118 
Animals and diets   119 
Thirty two 4-wk-old male weanling Sprague Dawley rats were randomly divided into 120 
four groups of eight animals.  The rats were maintained on an ad libitum normal chow 121 
diet with water, throughout the study. The total lipid content of the chow diet used was 122 
5.7 (g/100g of wet weight) and the three main unsaturated fatty acids present in the 123 
chow diet were oleic acid (OA) (29.7%), linoleic acid (31.2%) and ALA (3.4%); EPA, 124 
DPA and DHA were not detected. The rats were pair housed and allowed one week to 125 
acclimatise.  The rats were then administered 50mg of DPA, EPA, DHA or OA (Nu-126 
Chek Prep, Inc, USA) by daily oral gavaging for 7 days. The dose and duration used in 127 
this study was based on evidence from previously published studies which have 128 
successfully used doses of 90-100mg/d of PUFA, for rats weighing up to 140-220g. 129 
These studies demonstrated that changes in fatty acid composition of long chain PUFA 130 
occured within 3 days of supplementation 
(16-19)
. In the present study, we used 50mg of 131 
fatty acids for animals weighing 68-101g. Thus, it was expected that the dose of 50mg 132 
of fatty acids given for 7 days would be sufficient to detect changes in tissue fatty acid 133 
composition. 134 
The weight of the animals was recorded every day and on the 8
th
 day the animals 135 
were sacrificed by lethal injection of Lethobarb (Virbac, NSW, Australia).  Brain, heart, 136 
epididymal fat (adipose), skeletal muscle and liver were removed from the animals, 137 
washed in ice-cold saline (0.9% NaCl solution), and then dried on paper towel. After 138 
weighing the tissues were wrapped in foil and stored at -80ºC for fatty acid analysis.  139 
 140 
Lipid analysis 141 
The tissues were minced and the tissue lipids were extracted by chloroform/methanol 142 
2:1, as described by Sinclair et al 
(20)
. An aliquot of the total lipids from each tissue, plus 143 
an internal standard of docosatrienoic acid (22:3) (Nu-Chek Prep.USA), was  reacted 144 
with 2% H2SO4 in methanol for 3 hours at 80ºC to form the fatty acid methyl esters; 145 
they were passed through a silica sep-pak to remove cholesterol and then the fatty acid 146 
methyl esters were separated by capillary gas liquid chromatography using a 50 m x 147 
0.32 mm (I.D.) fused silica bonded phase column (BPX70, SGE, Melbourne, Australia).  148 
The column oven was programmed to rise after 3 min at 125° to 220°C at 8°C/min with 149 
a helium flow rate of 43 cm/sec as the carrier gas.  Fatty acids were identified by 150 
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comparison with standard mixtures of fatty acid methyl esters and the results were 151 
calculated using response factors derived from chromatographing standards of known 152 
composition (NuChek Prep., Inc, USA). 153 
 154 
Statistical analysis 155 
Data analysis was performed using SPSS v15.0 for Windows (SPSS Inc., Chicago, IL). 156 
Significant differences between dietary groups were tested using a one-way ANOVA for 157 
each type of fatty acid for both fatty acid analysis and gene expression.  Post-hoc 158 
comparisons were made using the LSD (least significant difference) test with a 159 
significance level of 0.05. 160 
 161 
Ethics approval 162 
All experimental procedures involving animals were performed under the ‘Australian 163 
code of practice for the care and use of animals for scientific purposes’ and were 164 
approved by La Trobe University Animal Ethics Committee (AEC07-53-P) and Deakin 165 
University Animal Welfare Committee (AEX 23/2008). 166 
 167 
RESULTS 168 
 169 
Body and tissue weights 170 
There was no significant difference in the body weights of animals between various dietary 171 
groups at the start and the end of the study.  The mean (±SD) body weights of rats at the start 172 
and end of study were 75.9 ± 5.8 and 122.4 ± 17.4 grams, respectively. There were no 173 
significant differences in the tissue weights between treatments. 174 
 175 
Tissue fatty acid concentrations 176 
 Adipose tissue contained the highest concentration of each of the three long chain n-177 
3PUFA with amounts ranging from 30 to 57 mg/g tissue compared with values of less 178 
than 3 mg/g in other tissues (Table 1).  In liver, muscle & brain tissue, the concentration 179 
of DHA was between 1 to 3 mg/g; for DPA, the concentration ranged from 0.1 to 2mg/g 180 
while for EPA the range was from 0.02 to 0.4mg/g tissue. The rats supplemented with 181 
DHA showed a significant increase in tissue DHA content in all the five tissues studied. 182 
The largest proportional increase in DHA occurred in adipose (3.4 fold) and skeletal 183 
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muscle (2.4 fold) and the least change was in brain (1.1 fold).  It was also observed that 184 
DHA supplementation led to a significant increase in EPA concentration in liver.  185 
DPA supplementation resulted in statistically significant accumulation of DPA 186 
in all tissues analysed except adipose tissue. DPA supplementation also led to a 187 
significant increase in EPA concentrations in liver, heart and skeletal muscle and a non-188 
significant increase in adipose tissue. Interestingly, DPA supplementation also led to a 189 
significant increase in DHA concentration in liver.  190 
Supplementation with EPA led to a significant increase in tissue EPA and DPA 191 
concentrations in liver, heart and skeletal muscle and a non-significant increase in 192 
adipose tissue. EPA supplementation also increased DHA concentrations significantly in 193 
liver. All the three n-3 PUFA led to a significant decrease in AA concentrations in liver 194 
and heart. 195 
 196 
DISCUSSION 197 
The aim of this study was to examine the effect of DPA supplementation on LCPn-3 198 
proportions in the tissues of animals fed 50mg of n-3 fatty acids per day for 7 days. It 199 
was observed that the primary site of DPA deposition was adipose followed by heart, 200 
liver and skeletal muscle. Adipose was also the main site for deposition of fed EPA and 201 
DHA in this study. Fu and Sinclair, reported that major sites of EPA and DPA 202 
deposition, in guinea pigs fed with diets containing 17.3% ALA (of total diet lipid) for 4 203 
weeks, were adipose, skin and carcass 
(10)
. 204 
It was observed that DPA supplementation increased DPA concentration in 205 
liver, heart, skeletal muscle and brain. It was also observed that DPA supplementation 206 
led to a significant increase in EPA concentrations in liver, heart and skeletal muscle 207 
and a non-significant increase in EPA concentrations in adipose tissue suggesting the 208 
retroconversion of DPA into EPA in vivo. The process of retroconversion was first 209 
described by Stoffel et al for DHA 
(21)
 and subsequent work by Christensen et al in 210 
human fibroblasts indicated the retroconversion of DHA and DPA were both likely to 211 
involve the peroxisomal acyl-CoA oxidase 
(22, 23)
. Retroconversion of DPA into EPA 212 
has also been reported in endothelial cells, fetal skin fibroblasts and hepatocytes 
(13, 14, 
213 
24)
. The extent of “apparent” retroconversion of DPA to EPA 214 
(EPA*100/[DPA+EPA]) was 28% in liver, 19% in adipose tissue, 12% in skeletal 215 
muscle, 4% in heart and negligible in brain.  216 
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It was also observed from our study that EPA fed animals showed a significant 217 
increase in EPA and DPA concentrations in the liver, heart and skeletal muscle. These 218 
data confirm the findings of previously published cell culture studies which showed that 219 
EPA is converted into DPA in endothelial and liver cells 
(13, 14)
. It is evident from our 220 
study that EPA and DPA are interconverted in the body and therefore DPA may act as a 221 
source of EPA in the body and vice-versa. This is particularly relevant in adipose tissue 222 
which had the highest concentrations of these PUFA and consequently adipose may act 223 
as a reservoir of these fatty acids. Supplementation with EPA had no effect on brain 224 
EPA levels which are known to very low (in this study 0.02mg/g). It has recently been 225 
suggested that low levels of EPA in brain phospholipids compared to DHA may be the 226 
result of its rapid beta oxidation upon uptake by the brain 
(25)
. 227 
Another very significant finding of our study was that supplementation of rats 228 
with DPA led to a significant increase in liver DHA concentrations and a non-229 
significant increase in brain, compared with the control group fed OA. The DPA fed 230 
group showed a 60% increase in liver DHA compared with the group fed DHA. Liver is 231 
regarded as a major site for PUFA synthesis 
(9)
 and since this was short-term study only, 232 
there may have been insufficient time for the increased liver DHA to be delivered to the 233 
other tissues via plasma lipoprotein transport. The two previously published cell culture 234 
studies that have looked at DPA supplementation failed to demonstrate an increase in 235 
tissue DHA levels. It is not clear whether this was due to a limited ability of these 236 
particular cells to desaturate PUFA or to competition between 24:5n-3 and ALA for 237 
metabolism to DHA 
(26)
. 238 
In this study, the DHA fed group was regarded as a control group to judge the 239 
effectiveness of increases in DHA concentration in the EPA- and DPA-fed groups. 240 
There was an increase in the tissue DHA concentrations in the DHA-fed group with the 241 
largest rise occuring in adipose tissue (3.4 fold), followed by skeletal muscle (2.4 fold), 242 
heart (2.1 fold), liver (1.76 fold) and brain (1.1 fold). It was no surprise that significant 243 
increases in DHA were observed as this has been observed by many groups in a variety 244 
of dietary supplementation studies 
(26-28)
. It was also observed that DHA 245 
supplementation increased the EPA levels in liver suggesting retroconversion into EPA.   246 
In this study, DPA, EPA and DHA supplementation also led to a significant 247 
decrease in tissue AA levels in liver and heart and a non significant decrease in muscle 248 
and adipose. This could be explained by the fact that n-3LCP are known to have an 249 
inhibitory effect on delta 6 and delta 5 desaturases (29, 30), which are involved in 250 
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synthesis of AA from linoleic acid. Also supplementation of cells with the LCPn-3 251 
could have led to competition for the enzyme acyl CoA transferase thereby decreasing 252 
the incorporation of AA into phospholipids 
(31)
.  253 
To our knowledge, so far there have been very few studies which have 254 
investigated the biochemical effects of DPA. We expect this might be due to the 255 
relatively limited availability and high cost of pure DPA. But in light of the present 256 
literature it can be speculated that the metabolic consequenses of accumulation of DPA 257 
in tissues may be related accumulation of DPA, EPA and DHA from DPA and to 258 
inhibition of AA metabolism. Two studies are worth mentioning since both reported an 259 
effect of pure DPA on platelet function through AA pathway inhibition 
(32, 33)
. One 260 
study reported that platelets metabolize 22:5n-3 into 11- and l4-hydroxy 261 
docosapentaenoic acids via an indomethacin-insensitive pathway 
(32)
. They also reported 262 
that when DPA is released along with AA in platelets it inhibited cycloxygenase (COX) 263 
enzyme thereby reducing the thromboxin B2 and 5,8,10-heptadecatrienoic acid (HHT) 264 
production from AA. Akiba et al (2000) looked at the effects of DPA on platelet 265 
aggregation and AA metabolism in rabbit platelets and compared them with those of 266 
EPA and DHA
(33)
. The results showed that n-3 fatty acids inhibited collagen- or AA-267 
stimulated platelet aggregation dose-dependently, and that DPA was the most potent 268 
inhibitor. These results suggest that DPA possesses potent activity for interfering with 269 
the COX pathway and accelerating the lipoxygenase pathway. 270 
 In conclusion, the data presented in our study demonstrated that oral 271 
consumption of dietary DPA in young male rats increased the concentration of DHA in 272 
liver but not other tissues. Furthermore, DPA was partially retroconverted to EPA in 273 
liver, muscle, adipose and heart.  Future studies should investigate the physiological & 274 
biochemical effects of DPA ingestion compared with that of EPA and DHA. 275 
 276 
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 308 
 309 
Figure 1: Pathway for metabolism of ALA to long chain n-3 PUFA.  310 
In mammals, some of the ingested ALA is metabolised to long chain n-3 fatty acids by 311 
series of elongations and desaturations. The figure shows the enzymes involved in this 312 
pathway. PUFA, polyunsaturated fatty acids; EPA, eicosapentaenoic acid; DPA, 313 
docosapentaenoic acid and DHA, docosahexaenoic acid. 314 
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TABLE 1: Tissue fatty acid concentrations in brain, adipose and skeletal muscle of 324 
animals in various dietary groups (mean ± SD)
 
325 
 326 
Fatty acid composition of various tissues from rats supplemented with 50 mg of OA, EPA, 327 
DPA or DHA for 7 days. Results are expressed as  mg/g of tissue (n=8). Mean±SD values 328 
within a row with unlike superscripts were significantly different (P<0.05). Data was analysed 329 
using one way ANOVA and post hoc comparisons were made using LSD. OA, Oleic acid; 330 
EPA, eicosapentaenoic acid; DPA, Docosapentaenoic acid; DHA, Docosahexaenoic acid. 331 
 332 
 333 
 334 
 335 
 336 
 337 
 338 
 339 
 340 
 341 
Fatty acids OA Control   EPA Group   DPA Group   DHA Group 
 Mean SD Mean SD Mean SD Mean SD 
Brain 
OA 2.97
a
 0.03 3.03
ab
 0.05 3.12
b
 0.05 3.10
ab
 0.06 
AA 2.01
a
   0.05 2.01
a
 0.04 2.03
a
 0.03 1.98
a
 0.05 
EPA 0.02
a
   0.00 0.02
a
   0.00 0.02
a
   0.00 0.03
a
 0.00 
DPA 0.08
a
 0.01 0.10
b
 0.01 0.11
b
 0.01 0.07
a
 0.00 
DHA 2.50
a
 0.05 2.62
ab
   0.03 2.65
ab
   0.06 2.70
b
  0.08 
Adipose 
  OA 948.33
a
 64.66 1031.55
a
 119.07 823.57
a
b
 
62.55 703.85
b
 50.27 
AA 40.48
a
 4.64 36.28
a
 5.79 31.88
 a
 2.95 29.28
a
 3.73 
EPA 3.87
a
 0.50 30.42
a
 7.95 14.37
a
 4.32 5.29
a
 0.90 
DPA 11.00
a
 2.48 29.96
a
 9.07 55.68
a
 13.73 23.48
a
 5.43 
DHA 16.62
a
 1.20 23.20
ab
 3.16 27.01
ab
 3.03 57.04
a
 10.23 
Skeletal Muscle 
OA 3.98
a
   0.68 3.95
a
   0.62 3.35
a
   0.48 3.62
a
 0.45 
AA 1.48
a
   0.08 1.26
 a
 0.03 1.23
a
 0.03 1.22
a
 0.02 
EPA 0.03
a
 0.00 0.23
b
 0.04 0.11
bc
 0.01 0.04
ac
 0.01 
DPA 0.27
a
 0.27 0.50
b
 0.03 0.87
c
 0.06 0.21
a
 0.02 
DHA 0.55
 a
   0.04 0.66
b
 0.03 0.61
ab
 0.02 1.31
c
 0.05 
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 342 
 343 
 344 
Figure 2: Fatty acid composition of liver tissue of rats supplemented with 50 mg of OA, EPA, 345 
DPA  or DHA for 7 days. Results are expressed as mg/g of tissue (n=8). Data was analysed 346 
using one way ANOVA and post hoc comparisons were made using LSD. Different 347 
superscripts represent significant difference from control OA group. 348 
OA, Oleic acid; EPA, eicosapentaenoic acid; DPA, Docosapentaenoic acid; DHA, 349 
Docosahexaenoic acid. 350 
 351 
 352 
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 353 
 354 
 355 
 356 
Figure 3: Fatty acid composition of heart tissue of rats supplemented with 50 mg of OA, EPA, 357 
DPA  or DHA for 7 days. Results are expressed as mg/g of tissue (n=8). Data was analysed 358 
using one way ANOVA and post hoc comparisons were made using LSD. Different 359 
superscripts represent significant difference from control OA group. 360 
OA, Oleic acid; EPA, eicosapentaenoic acid; DPA, Docosapentaenoic acid; DHA, 361 
Docosahexaenoic acid. 362 
 363 
 364 
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